HMC
TNGX icon

Harvard Management Company’s Tango Therapeutics TNGX Stock Holding History

Harvard Management Company’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-708,385
Closed -$7.98M – 19
2023
Q3 		$7.98M Hold
708,385
– – 0.9% 11
2023
Q2 		$2.35M Hold
708,385
– – 0.23% 22
2023
Q1 		$2.8M Hold
708,385
– – 0.29% 28
2022
Q4 		$5.14M Hold
708,385
– – 0.64% 24
2022
Q3 		$2.56M Hold
708,385
– – 0.32% 33
2022
Q2 		$3.21M Hold
708,385
– – 0.37% 29
2022
Q1 		$5.37M Hold
708,385
– – 0.54% 28
2021
Q4 		$7.75M Hold
708,385
– – 0.73% 27
2021
Q3 		$9.16M Buy
+708,385
New +$8.49M 0.54% 26

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Harvard Management Company's TNGX Position: Q4 2023 in Review

Harvard Management Company sold out of Tango Therapeutics (TNGX) in Q4 2023, closing a stake of 708,385 shares — an estimated $7.98M sold.

Harvard Management Company first reported a position in TNGX in Q3 2021 and held it in 9 quarters. The position peaked at $9.16M in Q3 2021. 121 funds tracked by Wall St. Rank hold TNGX as of Q4 2023.

  • Harvard Management Company reported no remaining Tango Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Harvard Management Company sold 708,385 Tango Therapeutics shares in Q4 2023, an estimated $7.98M.
  • Harvard Management Company first reported a position in Tango Therapeutics in Q3 2021 and held it in 9 quarters.
  • Harvard Management Company's Tango Therapeutics position peaked at $9.16M in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2023.

Based on Harvard Management Company's 13F filing for Q4 2023, filed 9 Feb 2024.